{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T21:38:17Z","timestamp":1784583497573,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"BioTime Inc","award":["2016-2559"],"award-info":[{"award-number":["2016-2559"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00262-020-02579-8","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T18:03:46Z","timestamp":1587751426000},"page":"1737-1749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity"],"prefix":"10.1007","volume":"69","author":[{"given":"Airi","family":"Harui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas I.","family":"Zarembinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2194-6578","authenticated-orcid":false,"given":"Michael D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"issue":"7598","key":"2579_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/532162a","volume":"532","author":"H Ledford","year":"2016","unstructured":"Ledford H (2016) Cocktails for cancer with a measure of immunotherapy. Nature 532(7598):162\u2013164. https:\/\/doi.org\/10.1038\/532162a","journal-title":"Nature"},{"issue":"1","key":"2579_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A (2019) Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 38(1):255. https:\/\/doi.org\/10.1186\/s13046-019-1259-z","journal-title":"J Exp Clin Cancer Res"},{"key":"2579_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fonc.2018.00315","volume":"8","author":"HT Marshall","year":"2018","unstructured":"Marshall HT, Djamgoz MBA (2018) Immuno-Oncology: Emerging Targets and Combination Therapies. Front Oncol 8:315. https:\/\/doi.org\/10.3389\/fonc.2018.00315","journal-title":"Front Oncol"},{"key":"2579_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3389\/fimmu.2019.00999","volume":"10","author":"B Seliger","year":"2019","unstructured":"Seliger B (2019) Combinatorial approaches with checkpoint inhibitors to enhance anti-tumor immunity. Front Immunol 10:999. https:\/\/doi.org\/10.3389\/fimmu.2019.00999","journal-title":"Front Immunol"},{"issue":"1","key":"2579_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"11","key":"2579_CR6","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD (2018) Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 19(11):1480\u20131492. https:\/\/doi.org\/10.1016\/S1470-2045(18)30700-9","journal-title":"Lancet Oncol"},{"issue":"21","key":"2579_CR7","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora JE, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS (2019) Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 381(21):2020\u20132031. https:\/\/doi.org\/10.1056\/NEJMoa1910231","journal-title":"N Engl J Med"},{"issue":"14","key":"2579_CR8","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, Plimack ER, Barth\u00e9l\u00e9my P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, CheckMate 214 Investigators (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 378(14):1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med."},{"issue":"8","key":"2579_CR9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Andr\u00e9 T (2018) Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 36(8):773\u2013779. https:\/\/doi.org\/10.1200\/JCO.2017.76.9901","journal-title":"J Clin Oncol"},{"issue":"3","key":"2579_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM (2015) Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 194(3):950\u2013959. https:\/\/doi.org\/10.4049\/jimmunol.1401686","journal-title":"J Immunol"},{"issue":"6","key":"2579_CR11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D, Allison JP (2017) Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170(6):1120\u20131133.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.07.024","journal-title":"Cell"},{"issue":"12","key":"2579_CR12","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"issue":"11","key":"2579_CR13","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","volume":"37","author":"C Lebb\u00e9","year":"2019","unstructured":"Lebb\u00e9 C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J (2019) Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 Trial. J Clin Oncol 37(11):867\u2013875. https:\/\/doi.org\/10.1200\/JCO.18.01998","journal-title":"J Clin Oncol"},{"issue":"9","key":"2579_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2579_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00262-017-2059-y","volume":"67","author":"JPO Hebb","year":"2018","unstructured":"Hebb JPO, Mosley AR, Vences-Catal\u00e1n F, Rajasekaran N, Ros\u00e9n A, Ellmark P, Felsher DW (2018) Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. Cancer Immunol Immunother 67(1):47\u201360. https:\/\/doi.org\/10.1007\/s00262-017-2059-y","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2579_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-016-1909-3","volume":"66","author":"P Ellmark","year":"2017","unstructured":"Ellmark P, Mangsbo SM, Furebring C, Norl\u00e9n P, T\u00f6tterman TH (2017) Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunol Immunother 66(1):1\u20137. https:\/\/doi.org\/10.1007\/s00262-016-1909-3","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"2579_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/jaut.1999.0272","volume":"12","author":"H Braley-Mullen","year":"1999","unstructured":"Braley-Mullen H, Sharp GC, Medling B, Tang H (1999) Spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J Autoimmun 12(3):157\u2013165","journal-title":"J Autoimmun"},{"issue":"1","key":"2579_CR18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/s12011-010-8815-x","volume":"143","author":"H Xue","year":"2011","unstructured":"Xue H, Wang W, Shan Z, Li Y, Li Y, Teng X, Gao Y, Fan C, Teng W (2011) Dynamic changes of CD4+CD25 + regulatory T cells in NOD.H-2h4 mice with iodine-induced autoimmune thyroiditis. Biol Trace Elem Res 143(1):292\u2013301. https:\/\/doi.org\/10.1007\/s12011-010-8815-x","journal-title":"Biol Trace Elem Res"},{"key":"2579_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/thy.2016.0092","volume":"8","author":"R Sharma","year":"2016","unstructured":"Sharma R, Di Dalmazi G, Caturegli P (2016) Exacerbation of autoimmune thyroiditis by CTLA-4 blockade: a role for IFN\u03b3-induced indoleamine 2, 3-dioxygenase. Thyroid 8:1117\u20131124. https:\/\/doi.org\/10.1089\/thy.2016.0092","journal-title":"Thyroid"},{"issue":"5","key":"2579_CR20","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1177\/0885328219867974","volume":"34","author":"A Harui","year":"2019","unstructured":"Harui A, Roth MD (2019) Employing a glutathione-s-transferase-tag and hyaluronidase to control cytokine retention and release from a hyaluronic acid hydrogel matrix. J Biomater Appl 34(5):631\u2013639. https:\/\/doi.org\/10.1177\/0885328219867974","journal-title":"J Biomater Appl"},{"issue":"9","key":"2579_CR21","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1210\/en.2010-0321","volume":"151","author":"C-R Chen","year":"2010","unstructured":"Chen C-R, Hamidi S, Braley-Mullen H, Nagayama Y, Bresee C, Aliesky HA, Rapoport B, McLachlan SM (2010) Antibodies to thyroid peroxidase arise spontaneously with age in NOD.H-2h4 mice and appear after thyroglobulin antibodies. Endocrinology 151(9):4583\u20134593. https:\/\/doi.org\/10.1210\/en.2010-0321","journal-title":"Endocrinology"},{"key":"2579_CR22","doi-asserted-by":"publisher","first-page":"h988","DOI":"10.1136\/bmj.h988","volume":"350","author":"LH Butterfield","year":"2015","unstructured":"Butterfield LH (2015) Cancer vaccines. BMJ 350:h988. https:\/\/doi.org\/10.1136\/bmj.h988","journal-title":"BMJ"},{"issue":"6","key":"2579_CR23","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1084\/jem.20182395","volume":"216","author":"JM Fritz","year":"2019","unstructured":"Fritz JM, Lenardo MJ (2019) Development of immune checkpoint therapy for cancer. J Exp Med 216(6):1244\u20131254. https:\/\/doi.org\/10.1084\/jem.20182395","journal-title":"J Exp Med"},{"issue":"25","key":"2579_CR24","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate 026 Investigators (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 376(25):2415\u20132426. https:\/\/doi.org\/10.1056\/NEJMoa1613493","journal-title":"N Engl J Med"},{"issue":"19","key":"2579_CR25","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1158\/1078-0432.CCR-12-0781","volume":"19","author":"MF Fransen","year":"2013","unstructured":"Fransen MF, van der Sluis TC, Ossendorp F, Arens R, Melief CJ (2013) Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res 19(19):5381\u20135389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0781","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2579_CR26","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-10-2888","volume":"17","author":"MF Fransen","year":"2011","unstructured":"Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ (2011) Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 17(8):2270\u20132280. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2888","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2579_CR27","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1038\/s41598-019-41724-x","volume":"9","author":"K Narumi","year":"2019","unstructured":"Narumi K, Miyakawa R, Shibasaki C, Henmi M, Mizoguchi Y, Ueda R, Hashimoto H, Hiraoka N, Yoshida T, Aoki K (2019) Local administration of GITR agonistic antibody induces a stronger antitumor immunity than systemic delivery. Sci Rep 9(1):5562. https:\/\/doi.org\/10.1038\/s41598-019-41724-x","journal-title":"Sci Rep"},{"issue":"6","key":"2579_CR28","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1172\/JCI64859","volume":"123","author":"A Marabelle","year":"2013","unstructured":"Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R (2013) Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest 123(6):2447\u20132463. https:\/\/doi.org\/10.1172\/JCI64859","journal-title":"J Clin Invest"},{"issue":"9","key":"2579_CR29","doi-asserted-by":"publisher","first-page":"e0161779","DOI":"10.1371\/journal.pone.0161779","volume":"11","author":"MJ Selby","year":"2016","unstructured":"Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D, Quigley M, Valle J, Wang C, Chen B, Cardarelli PM, Blanset D, Korman AJ (2016) Preclinical development of Ipilimumab and Nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS ONE 11(9):e0161779. https:\/\/doi.org\/10.1371\/journal.pone.0161779","journal-title":"PLoS ONE"},{"issue":"1","key":"2579_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1158\/1078-0432.CCR-08-0783","volume":"15","author":"A Ribas","year":"2009","unstructured":"Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ (2009) Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res 15(1):390\u2013399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0783","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2579_CR31","doi-asserted-by":"publisher","first-page":"E407","DOI":"10.3390\/pharmaceutics11080407","volume":"11","author":"S Trombino","year":"2019","unstructured":"Trombino S, Servidio C, Curcio F, Cassano R (2019) Strategies for hyaluronic acid-based hydrogel design in drug delivery. Pharmaceutics. 11(8):E407. https:\/\/doi.org\/10.3390\/pharmaceutics11080407","journal-title":"Pharmaceutics."},{"issue":"6","key":"2579_CR32","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1097\/SAP.0000000000001194","volume":"79","author":"CP Blackshear","year":"2017","unstructured":"Blackshear CP, Flacco JS, Vistnes SM, Chung NN, Irizarry D, Brett EA, Yen DJ, Momeni A, Longaker MT, Wan DC (2017) Cell-based soft tissue reconstruction in a hydrogel scaffold. Ann Plast Surg 79(6):618\u2013622. https:\/\/doi.org\/10.1097\/SAP.0000000000001194","journal-title":"Ann Plast Surg"},{"issue":"2","key":"2579_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebb\u00e9 C (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155\u2013164. https:\/\/doi.org\/10.1016\/S1470-2045(09)70334-1","journal-title":"Lancet Oncol"},{"issue":"2","key":"2579_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/eji.201646583","volume":"47","author":"L van Hooren","year":"2017","unstructured":"van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, T\u00f6tterman TH, Mangsbo SM (2017) Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. Eur J Immunol 47(2):385\u2013393. https:\/\/doi.org\/10.1002\/eji.201646583","journal-title":"Eur J Immunol"},{"key":"2579_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","volume":"286","author":"M Viola","year":"2018","unstructured":"Viola M, Sequeira J, Sei\u00e7a R, Veiga F, Serra J, Santos AC, Ribeiro AJ (2018) Subcutaneous delivery of monoclonal antibodies: how do we get there? J Control Release 286:301\u2013314. https:\/\/doi.org\/10.1016\/j.jconrel.2018.08.001","journal-title":"J Control Release"},{"issue":"12","key":"2579_CR36","doi-asserted-by":"publisher","first-page":"7635","DOI":"10.4049\/jimmunol.0804251","volume":"183","author":"KM Wheeler","year":"2009","unstructured":"Wheeler KM, Samy ET, Tung KS (2009) Cutting edge: normal regional lymph node enrichment of antigen-specific regulatory T cells with autoimmune disease-suppressive capacity. J Immunol 183(12):7635\u20137638. https:\/\/doi.org\/10.4049\/jimmunol.0804251","journal-title":"J Immunol"},{"issue":"2","key":"2579_CR37","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1530\/ERC-13-0499","volume":"21","author":"M Ryder","year":"2014","unstructured":"Ryder M, Callahan M, Postow MA, Wolchok J, Fagin JA (2014) Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 21(2):371\u2013381. https:\/\/doi.org\/10.1530\/ERC-13-0499","journal-title":"Endocr Relat Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02579-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T05:11:35Z","timestamp":1619327495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02579-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2579"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02579-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"assertion":[{"value":"26 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs. Roth and Harui report grants and non-financial support from BioTime Inc. during the conduct of the study and institutional submission of a patent application. Dr. Zarembinski was previously a Senior Director, Alliance Management and External R&D Collaborations, BioTime Inc., Alameda, CA. Professors McLachlan and Rapoport declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}